Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (ANAB)
NASDAQ:ANAB
AnaptysBio (ANAB) Stock Price & Analysis
314 Followers
ANAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.36 - $27.50
Previous Close$19.87
Volume288.94K
Average Volume (3M)324.54K
Market Cap
$530.71M
Enterprise Value$157.62M
Total Cash (Recent Filing)$390.90M
Total Debt (Recent Filing)$17.81M
Price to Earnings (P/E)-3.3
Beta0.47
Next Earnings
May 08, 2024EPS Estimate
-$1.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.07
Shares Outstanding26,763,081
10 Day Avg. Volume327,571
30 Day Avg. Volume324,543
Standard Deviation0.21
R-Squared0.00540
Alpha0.00460
Financial Highlights & Ratios
Price to Book (P/B)6.02
Price to Sales (P/S)59.05
Price to Cash Flow (P/CF)-3.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.19
Enterprise Value/Gross Profit9.19
Enterprise Value/Ebitda-0.98
Forecast
1Y Price Target
$50.00Price Target Upside151.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
AnaptysBio News
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company's cash and equivalents are reported to be sufficient to fund operations, indicating a stable financial position.
Innovative R&DAnaptysBio is a clinical stage biotechnology company that uses its somatic hypermutation platform to develop checkpoint mAbs antibodies with a focus in inflammatory disease and oncology.
Pipeline ProgressionThe phase 2b study of ANB032 in atopic dermatitis and the phase 2 study of rosnilimab in rheumatoid arthritis are progressing as planned.
Bears Say
Clinical Trial OutcomesIn the event that Eli Lilly discontinues peresolimab or reports confounding Phase 2b efficacy data, there could be a substantial downside risk for ANAB shares.
Competitive Product EfficacyCompetitor Lilly's peresolimab showed limited depth of response, indicating potential for rosnilimab to outperform.
Financial PerformanceANAB reported a net loss of $42MM.
---
Ownership Overview
70.24% Insiders
14.98% Mutual Funds
12.73% Other Institutional Investors
2.05% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANAB FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $13.36 and its highest was $27.50 in the past 12 months.
What is AnaptysBio Inc’s market cap?
Currently, no data Available
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is May 08, 2024 which is in 13 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on Mar 11, 2024. The company reported -$1.59 earnings per share for the quarter, beating the consensus estimate of -$1.601 by $0.011.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is -$1.57.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 26,763,080 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of -$1.59 in its last earnings report, beating expectations of -$1.601. Following the earnings report the stock price went up 11.606%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Among the largest hedge funds holding AnaptysBio Inc’s share is Woodline Partners LP. It holds AnaptysBio Inc’s shares valued at 26M.
---
AnaptysBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.00 (151.64% Upside)
$50.00 (151.64% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 252.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.1%
Last 30 Days ▼ 15.8%
Last 30 Days ▼ 15.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.87%
12-Months-Change
Fundamentals
Return on Equity
-93.44%
Trailing 12-Months
Asset Growth
-25.88%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
---
ANAB Stock 12 Months Forecast
Average Price Target
$50.00
▲(151.64% Upside)
Technical Analysis
Best Analysts Covering ANAB
1 Year
1 Year Success Rate
3/8 ratings generated profit
1 Year Average Return
-24.45%
reiterated a buy rating 6 months ago
Copying Yatin Suneja's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -24.45% per trade.
---